Betulinic acid 是一種天然的五環(huán)三萜類(lèi)化合物，為真核細(xì)胞拓?fù)洚悩?gòu)酶 I (topoisomerase I) 的抑制劑，IC50 值為 5 μM，具有抗炎，抗瘧疾，抗艾滋病和抗腫瘤等活性。
Betulinic acid is a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and prevents topoisomerase I-DNA interaction[1]. Betulinic acid (10, 20, 40, 80, and 160 μM) significantly suppresses MDA-MB-231 cell viability in a time- and dose-dependent manner after treatment for 24 or 48 h. Betulinic acid (20, 40 μM) causes decrease in Bcl-2 expression of MDA-MB-231 cells. Betulinic acid also induces morphological changes of MDA-MB-231 cells at 20 μM, and leads to ultrastructure changes of MDA-MB-231 cells at 40 μM[2]. Betulinic acid shows anti-HIV activities, with an EC50 of 1.4 μM in acutely infected H9 lymphocytes[4].
Betulinic acid (10 and 30 mg/kg, p.o.) significantly abrogates colon shortening, and reduces malondialdehyde (MDA) and lipid hydroperoxide levels in dextran sulfate sodium (DSS)-induced colitis in mice. Betulinic acid (30 mg/kg, p.o.) restores superoxide dismutase (SOD), catalase activity and glutathione (GSH) content to control levels in DSS-induced colitis in mice. Betulinic acid (30 mg/kg, p.o.) also inhibits the DSS-induced increase in inflammatory markers. Betulinic acid (3, 10, 30 mg/kg, p.o.) suppresses acetic acid-induced writhing responses and mustard oil (MO)-induced visceral nociception in mice[3].
關(guān)鍵字： 472-15-1;
廣州優(yōu)南科技有限公司，是一家集研發(fā)、生產(chǎn)、銷(xiāo)售于一體的高新技術(shù)企業(yè)，為全球生物醫(yī)藥企業(yè)、高校及科研院提供生命科學(xué)研究的產(chǎn)品與服務(wù)。
優(yōu)南擁有自主研發(fā)的品牌ULS，為客戶(hù)提供超過(guò)50000的工具化合物(小分子抑制劑/激動(dòng)劑、標(biāo)準(zhǔn)品/對(duì)照品、熒光標(biāo)記染料及探針)、醫(yī)藥原料及中間體、新型材料。